HCM Sovleplenib NDA Accepted in China with Priority Review

HUTCHMED (China) Ltd announced that its New Drug Application (NDA) for sovleplenib has been accepted in China. The NDA, which seeks approval for the treatment of warm antibody autoimmune hemolytic anemia, has been granted both priority review status and breakthrough designation by China's National Medical Products Administration (NMPA). This accelerates the potential market entry for the drug in China.